Who Paid My Doc
Henry Bone
Endocrinology, Diabetes & Metabolism Detroit, MI Medical Doctor
NPI 1598760688 CMS profile 299410
22201 Moross Rd, Ste 260, Detroit, MI 48236
General payments
$119,993
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$19,999
Through program year 2025, Henry Bone of Detroit, MI is reported in the CMS Open Payments database as having received $119,993 across 127 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $19,999 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 93rd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $92 | 2 | |
| 2023 | General | $8,769 | 10 | |
| 2022 | General | $13,262 | 6 | |
| 2021 | General | $4,507 | 5 | |
| 2020 | General | $9,683 | 12 | |
| 2019 | General | $83,681 | 92 |
Beside peers
- Henry Bone
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Henry Bone were reported at $92. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Henry Bone | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $83,681 | $494 | $123–$2,253 | $163 |
| 2020 | $9,683 | $335 | $85–$1,841 | $114 |
| 2021 | $4,507 | $398 | $88–$1,981 | $132 |
| 2022 | $13,262 | $364 | $88–$1,568 | $149 |
| 2023 | $8,769 | $420 | $113–$1,614 | $160 |
| 2024 | $0 | $440 | $121–$1,646 | $164 |
| 2025 | $92 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
443
Drug cost
$17,443
Branded share of claims
13.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cinacalcet Hcl | Generic | 26 | $6,900 | |
| Raloxifene Hcl | Generic | 66 | $3,263 | |
| Amiloride-Hydrochlorothiazide Amiloride/Hydrochlorothiazide | Brand | 60 | $2,407 | |
| Indapamide | Generic | 117 | $1,624 | |
| Calcitriol | Generic | 51 | $1,202 | |
| Alendronate Sodium | Generic | 86 | $1,139 | |
| Potassium Chloride | Generic | 25 | $820 | |
| Levothyroxine Sodium | Generic | 12 | $88 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 7 billing codesPaid by Medicare
$58,060
Medicare patients
302
Services billed
749
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Osteoporosis | 75% | |
| High blood pressure | 60% | |
| Arthritis | 56% | |
| Chronic kidney disease | 28% | |
| Cancer | 23% | |
| Ischemic heart disease | 22% | |
| Atrial fibrillation | 17% | |
| Depression | 14% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
127 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in Michigan
Lowell Schmeltz
Endocrinology, Diabetes & Metabolism · Farmington Hills, MI
George Grunberger
Endocrinology, Diabetes & Metabolism · Bloomfield Hills, MI
Gary Edelson
Endocrinology, Diabetes & Metabolism · Farmington Hills, MI
Michael Brennan
Endocrinology, Diabetes & Metabolism · Saint Clair Shores, MI
Jamal Hammoud
Endocrinology, Diabetes & Metabolism · Flint, MI
Abdulsalam Al Kassab
Endocrinology, Diabetes & Metabolism · Rochester Hills, MI
Related records
Endocrinology, Diabetes & Metabolism in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.